BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26666746)

  • 1. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
    Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
    Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
    Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
    Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
    Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
    Lin P; Owens R; Tricot G; Wilson CS
    Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
    Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
    Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
    Perfetti V; Vignarelli MC; Bellotti V; Glennie MJ; Zorzoli I; Ubbiali P; Obici L; Massa M; Ippoliti G; Ascari E; Merlini G
    Lab Invest; 1997 Oct; 77(4):333-44. PubMed ID: 9354768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD52 on plasma cells in plasma cell proliferative disorders.
    Kumar S; Kimlinger TK; Lust JA; Donovan K; Witzig TE
    Blood; 2003 Aug; 102(3):1075-7. PubMed ID: 12714489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotype of neoplastic plasma cells in AL amyloidosis.
    Deshmukh M; Elderfield K; Rahemtulla A; Naresh KN
    J Clin Pathol; 2009 Aug; 62(8):724-30. PubMed ID: 19638544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
    Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an unbiased, semi-automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates.
    Post SR; Post GR; Nikolic D; Owens R; Insuasti-Beltran G
    Cytometry B Clin Cytom; 2018 Sep; 94(5):602-610. PubMed ID: 29573142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
    Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
    Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
    Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
    Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
    Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
    Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
    Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P
    Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
    Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
    Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
    Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
    Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
    Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
    Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD52 is not a promising immunotherapy target for most patients with multiple myeloma.
    Westermann J; Maschmeyer G; van Lessen A; Dörken B; Pezzutto A
    Int J Hematol; 2005 Oct; 82(3):248-50. PubMed ID: 16207599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.